Credit Suisse Maintains Neutral on Quest Diagnostics, Lowers Price Target to $143
Credit Suisse analyst A.J. Rice maintains Quest Diagnostics (NYSE:DGX) with a Neutral and lowers the price target from $158 to $143.
Related Posts
Morgan Stanley Maintains Overweight on PACCAR, Raises Price Target to $146
Morgan Stanley analyst Dillon Cumming maintains PACCAR (NASDAQ:PCAR) with a Overweight and raises the price target from $136 to $146.
ChatGPT’s Meteoric Rise Faces Traffic Downturn Three Months In A Row Amid App Expansions And Rising Rivals
Despite its initial rapid growth, OpenAI's ChatGPT faced its third consecutive month of declining website traffic while facing competition from other tech giants' chatbot offerings.
Australia Grants Equinor Feasibility License For Offshore Wind Project: Report
Australian govt grants Equinor & Oceanex Energy a license to assess feasibility of constructing wind farm. PM aims for 82% of power from renewables by 2030.